NCT01914211

Brief Summary

This is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2013

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 31, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 2, 2013

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

February 1, 2017

Status Verified

January 1, 2017

Enrollment Period

11 months

First QC Date

July 31, 2013

Last Update Submit

January 31, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Level of postoperative hemostasis

    Evaluating the body's ability to stop or decrease postoperative bleeding.

    24 hours

Secondary Outcomes (1)

  • Volume of blood transfusions

    24 hours

Study Arms (2)

Acute Normovolemic Hemodilution

Patients that receive acute normovolemic hemodilution prior to surgery.

Procedure: Acute Normovolemic Hemodilution

Tranexamic Acid

Patients that receive tranexamic acid during surgery.

Drug: Tranexamic Acid

Interventions

100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.

Tranexamic Acid

Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)

Acute Normovolemic Hemodilution

Eligibility Criteria

AgeUp to 28 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Patients from the cardiothoracic surgery population at Nationwide Children's Hospital.

You may qualify if:

  • All neonates undergoing arterial switch or aortic arch procedure utilizing cardiopulmonary bypass (CPB).

You may not qualify if:

  • Jehovah's witness patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Location

MeSH Terms

Conditions

Heart Defects, Congenital

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of Pediatric Cardiothoracic Anesthesia

Study Record Dates

First Submitted

July 31, 2013

First Posted

August 2, 2013

Study Start

July 1, 2013

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

February 1, 2017

Record last verified: 2017-01

Locations